A Phase I/II Trial of Venetoclax and BEAM Conditioning Followed by Autologous Stem Cell Transplantation for Patients With Primary Refractory Non-Hodgkin Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Carmustine (Primary) ; Cytarabine (Primary) ; Etoposide (Primary) ; Melphalan (Primary) ; Venetoclax (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 06 Nov 2019 Results from Dose-escalation part released at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem 2019).
- 16 Jul 2018 Status changed from not yet recruiting to recruiting.
- 16 Jul 2018 New trial record